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Figure 1 - Grey board: classical Au complexes used in crysotherapy, including aurothioglucose (solganol), aurothiomalate (2) and 
auranofin (3). Blue board: Au(I) compounds (4-7) designed by de Paiva et al.[3] as probes of the topography of the HIV-1 nucleocapsid 
zinc finger protein. Light green board: Au(I,III) compounds (8-15) studied by Meier et al.[5] and de Almeida et al.[6] for understanding 
the molecular basis of the interactions with selected biomolecules. Dark green board: gold(III) dithiocarbamate complexes (16 and 
17) investigated by Wang et al.[7] as inhibitors of amyloid fibril formation. Yellow board: gold(I,III) complexes (18-22) evaluated 
by Massai et al.[8] as Cys-protease inhibitors and as antiparasitic agents. Purple board: Alkyne gold(I) compounds (23-30) studied 
as anticancer agents by García-Moreno and co-authors.[9]  Orange board: Au(I) carbene compounds  coupled to ferrocene moieties 
(31 and 32) investigated by Muenzner et al.[10] as anticancer agents. Red board: gold(III) organometallic compound (33) evaluated 
against Gram-positive and Gram-negative bacterial strains.[11]
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ABSTRACT
Gold-based metallodrugs have been studied for a wide variety of medical–related applications, 
although the antiarthritic auranofin is the only representative within this class that has reached 
the clinic. Platinum compounds, on the other hand, are the leading class of metallodrugs used 
against cancer, with very successful representatives worldwide, such as cisplatin, carboplatin and 
oxaliplatin. In this mini review, we will briefly present the development of gold- and platinum
-based metallodrugs throughout the year of 2017.
1. Introduction
Medicinal applications of gold date to antiquity. 
The oldest records, dated to around 2500 BC, indicate 
that the Chinese and Arabians were the first to use gold 
for therapeutic purposes.[1,2] In the 8th century it was 
considered as an elixir of youth.[2] In the 19th century, 
sodium tetrachloridoaurate(I), Na[AuCl4], was prescribed 
to treat syphilis and chronic alcoholism.  In the end of 
the 19th century, Robert Koch first described the activities 
of potassium dicyanidoaurate(I), K[Au(CN)2] for the 
treatment of tuberculosis.[2] With the development of 
modern Medicine and the emergence of new technologies, 
the empirical use of gold was replaced by a more rational 
design of gold-based medicine, to circumvent the toxic 
effects of K[Au(CN)2]. This approach was responsible for 
the development of aurothioglucose (Solganol), myocrisin 
and later of auranofin, compounds used in the treatment 
rheumatoid arthritis. Curiously enough, the first uses of 
gold(I) compounds in treatment of rheumatoid arthritis 
were based on the idea that such illness was caused by 
a bacterial infection, which was shown to be incorrect.
[1] Mirroring the historical application of gold and gold-
containing compounds for the treatment of such a wide 
variety of diseases, the 2016-2017 period has introduced 
gold-based metallodrugs for applications including the 
molecular understanding of the mechanisms of interaction 
with protein targets[3–8] and development of new therapeutic 
agents for HIV, cancer, [9,10]  bacterial infections[11] as well 
as parasitic infections.[12]
Platinum compounds, on the other hand, were 
intensively studied since the middle 1960’s after the 
serendipitous discovery of the antitumor activity of cisplatin 
by Rosenberg.[13,14] Cisplatin revolutionized the treatment 
of testicular cancer, leading to cure rates higher than 
95%. The mechanism of action of cisplatin is generalized 
as dependent of 4 steps: cellular uptake, aquation 
(replacement of the leaving ligands by water molecules, 
DNA binding (leading to a bending along the helical axis) 
and finally cellular processing, including recognition of 
the damage, which ultimately leads to cell death.[15] A 
well-stablished structure-activity relationship for cisplatin 
has been rationalized, and it relies on a square planar Pt(II) 
center surrounded by monodentate or chelating N-donors 
(non-leaving groups) and negatively charged monodentate 
or bidentate ligands (leaving ligands). Oxaliplatin and 
carboplatin were rationally developed expanding on the 
general structure of cisplatin. Both compounds feature 
bidentate ligands that are replaced by water molecules 
more slowly than the monodentate chlorides found in 
the structure of cisplatin.[16,17] Platinum drugs have been 
listed on the 2013’s edition of the Model List of Essential 
Medicines of the World Health Organization, which 
highlights the relevance of this class of compounds and 
justifies the extensive research in the field. Some hand-
picked examples published in the previous year will be 
discussed here. Within this period, we also highlight the 
breakthrough discovery regarding the mechanism of action 
of oxaliplatin, which was demonstrated to be significantly 
different from that of cisplatin and carboplatin.[18] 
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2. Recent advances on Au(I,III) chemistry in 
the context of Bioinorganic Chemistry
Figure 1 shows gold-based metallodrugs published in 
the literature from 2016 to 2017. 
Protein targeting and inhibition
A series of thiophilic Au(I)-phosphine compounds (3-7) 
was evaluated by Paiva et al.[3] for chemoselective auration 
of the C-terminal HIV nucleocapsid protein NCp7 zinc 
finger 2 (F2) and the full-length HIV NCp7 (NC), as probes 
of nucleocapsid topography. The nature of the phosphine 
and the co-ligand affect the reactivity with the C-terminal 
NCp7 F2 and the full-length NC. 31P NMR spectroscopy 
showed the formation of long-lived {Au(PR3)}−ZnF 
species in all cases, but a selective interaction was 
observed for the dmap-containing compound 5 with NCp7 
F2. Auranofin (3) led to an unusual Au−His (rather than 
Au−Cys) coordination to NCp7. Modification of the fully 
functional NC zinc finger by Cy3P-containing species 
(6 and 7) inhibited the NC−SL2 DNA interaction, as 
evaluated by fluorescence polarization. 
Traveling Wave Ion Mobility-Mass Spectrometry 
(TWIM-MS) was used by Du, Paiva and Farrell[4] to 
investigate the possible coordination isomerism of 
Au(I) metallopeptide ions obtained by the interaction 
of compound 4 with the zinc fingers NCp7 F2 and Sp1 
F3 (where Sp1 is the human transcription factor). Two 
conformers of the NCp7 F2 “gold finger” were identified in 
the gas phase using TWIM-MS, while a single conformer 
was identified for the Sp1 F3 “gold finger”. Collision 
induced dissociation allowed an unequivocal assignment 
of the Au(I) binding sites for the major conformers 
obtained in each reaction. A Cys-Au-Cys coordination was 
identified for NCp7 F2 “gold finger”, while a Cys-Au-His 
coordination was observed for the Sp1 F3 “gold finger”.
Meier et al. studied the interaction of a series of 
gold(III) compounds (both organometallic and coordi-
nation, 8-12) with biologically relevant nucleophiles by 
ESI-MS.[5] Compound 8 reacts readily with 9-ethylgua-
nine (EtG). Organometallic compounds 9 and 10 show 
only very minor MS signals for EtG adducts even after 
24 h. Readily detectable EtG adducts were observed for 
11. Compounds 11 and 12 form adducts with cytochrome 
c (cyt) to a greater extent than 9 and 10 do. Compound 
8 did not form any adducts with either ubiquitin (ub) or 
cyt. Compounds 9 and 10 formed mono- and bis-adducts 
of the type [protein+(L)nAu(III)]+ (L is the respective C,N 
bidentate ligand; n = 1 or 2) with both proteins to a sim-
ilar extent. Complexes 11 and 12 reacted similarly with 
both proteins, even leading to the formation of higher 
order adducts. Compound 8 reacted preferentially with 
Se-Cys, 9 with Cys, and 10 with His, whereas 11 and 12 
undergo redox reactions and oxidize Cys to cystine. The 
molecular reactivity patterns and binding preferences cor-
related with the inhibition of TrxR1, i.e., Se-Cys binding 
leads to potent TrxR1 inhibitors and in some cases to a 
high antiproliferative activity. The binding preferences 
imply that the families of coordination and organometallic 
Au(III) anticancer agents follow different modes of action. 
The inhibition of human aquaporin (AQP3) was 
evaluated by a series of Au(III) complexes (10, 11, 13, 14 
and 15) was investigated by Almeida et al. [6] The cationic 
complex 15 was identified as the most potent inhibitor of 
glycerol permeation. The neutral complex 14, with a similar 
ligand system, was scarcely active. DFT studies showed 
a good correlation between the compound’s calculated 
affinity to cysteine residues and their AQP3 inhibition. 
Electrochemistry demonstrated that AQP3 inhibition is 
not related to oxidative damage. Molecular Dynamics 
studies demonstrated that binding of the compounds to 
one monomer also affects substrate permeability in an 
adjacent one. The Au(III) complexes were also shown to 
be cytotoxic in vitro and AQP3 inhibition might contribute 
to the biological effects observed towards cancer cells. 
Wang et al.[7] investigated the inhibition amyloid 
fibril formation by gold dithiocarbamate complexes. 
Thioflavin fluorescence assay (added to samples of the 
peptides PrP106-126 and hIAPP incubated with the gold 
compounds), supported by TEM and DLS measurements, 
revealed that complexes 16 and 17 effectively inhibited 
fibril formation. Auranofin (3) had only limited effects. In 
terms of binding sites, histidine was pointed as a potential 
target in both PrP106-126 and hIAPP.  
A panel of Au(I) and Au(III) coordination and 
organometallic compounds (2, 3, 8, 18-22) was evaluated 
in terms of inhibition of human and parasitic Cys-proteases 
(Proteasome (CT-L), Cathepsin B, Cathepsin L, Rhodesain 
and CPB2.8ΔCTE).[8] Compounds 8, 19, 20 and 22 were 
found to be potent inhibitors of human cathepsins (B and 
L) and of L. mexicana cysteine protease CPB2.8DCTE. 
The compounds showed sub-micromolar antiproliferative 
activity against L. infantum, T. cruzi, T. brucei, T. 
rhodesiense and P. falciparum, but were also shown to 
be cytotoxic against the model host cell lines MCR-5 and 
PMM. 
Antiproliferative activities
A series of gold(I)-alkyne derivatives containing the 
water soluble phosphines PTA (1,3,5-triaza-7-phosphaa-
damantane) and DAPTA (3,7-diacetyl-1,3,7-triaza-5-phos-
phabicyclo[3.3.1]nonane) (compounds 23-30) were tested 
against the human colon cancer cell line Caco-2 (PD7 
and TC7 clones).[9] PTA-containing compounds were more 
cytotoxic than DAPTA-containing analogs, which correlat-
ed well with the higher cellular uptake of the former. The 
anticancer activity of 23 against colon cancer cell lines 
happens through the apoptotic pathway and induction of 
S-phase arrest in the cell cycle. An increase in the mean 
survival time and life expectancy in athymic nude mice 
xenografted with human HCT -116-luc2 cancer cells was 
observed, with moderate inhibition of tumor growth.[9] 
Muenzner et al.[10] investigated the antiproliferative 
and antivascular properties gold(I) carbene complexes 
featuring 4-ferrocenyl-substituted imidazol-2-ylidene 
ligands (31 and 32 were selected as examples). The series 
had low micromolar to nanomolar IC50 (72 h) values 
against a panel of seven cancer cells. The lipophilic 
cationic complexes 31 and 32 caused an increase in reactive 
oxygen species by a ferrocene-dependent mechanism and 
by inhibition thioredoxin reductase. Both complexes led to 
a G1 phase cell cycle arrest and a retarded cell migration. 
Antiangiogenic effect was demonstrated by tube formation 
assays with endothelial cells. The biscarbene complex 32 
lead to up to 80% xenograft tumor volume reduction in mice.
Antimicrobial properties
The novel heteroleptic cyclometalated 
complex [AuIII(pyb-H)(mnt)] (33) was tested 
against a panel of ten Gram-positive (belonging to 
the Staphylococcus, Streptococcus spp. and Bacillus 
clausii) and Gram-negative (E. coli, K. pneumoniae, P. 
aeruginosa) bacteria and three yeasts belonging to 
the Candida species. Complex 33 showed a remarkable 
bacteriostatic antimicrobial activity against Staphylococci, 
with Minimum Inhibitory Concentration (MIC) values of 
1.56 and 3.13 μg/mL for S. haemoliticus and S. aureus, 
respectively. [11]
Antiparasitic properties
In a Phase 1 clinical trial, auranofin (1) was identified 
as a broad-spectrum antiparasitic drug, being effective 
in vitro and in vivo against Entamoeba histolytica and 
both metronidazole-sensitive and -resistant strains of 
Giardia intestinalis.[13]  Both parasites are the major 
causes of water and foodborne diseases. Patients were 
treated daily with 6 mg of auranofin, which corresponds 
to the recommended dose for arthritis treatment. Besides 
the 7 days treatment period, the patients were followed 
for 126 days. A concentration of 13 μM  (in auranofin 
equivalents) was found in feces at the 7th day of treatment, 
which corresponds to more than 25 fold the IC50 for E. 
histolytica and 4 fold that of Giardia. 
3. Recent advances on Pt(II,IV) chemistry in the 
context of Bioinorganic Chemistry
Platinum compounds are still the leading metallodrugs 
and platinum chemistry with bioinorganic applications 
has been extensively explored. For that reason, we had to 
handpick the most noteworthy examples of platinum(II, 
Figure 2 - Grey board: classical 
platinum(II) compounds cisplatin 
(34), oxaliplatin (35) and 
carboplatin (36). Orange board: 
platinum(II) complex (37) used 
by Rivilla and co-authors[19] for 
catalyzing 1,3-dipolar reactions of 
azomethine ylides with maleimides 
using platinated DNA systems 
coupled with copper(II). Green 
board: Platinum(IV) biotinylated 
systems (38 and 39) designed by 
Muhammad and co-authors as 
cytotoxic agents.[20] Yellow board: 
platinum(II) compound (40) 
designed by Zhu and co-authors[21] 
as probes for lipopolysaccharide 
endotoxin and discrimination 
between Gram-negative and Gram-
positive bacterial strains.  Blue 
board: platinum(II) compounds 
(41-52) designed by Tsotsoros and 
co-authors[22] containing the general 
motif [Pt(chelate)(N-donor)]2+ and 
evaluated as anti-HIV agents. Purple 
board: Peterson and co-authors[23] 
demonstrated that the polynuclear 
platinum compounds triplatin (53) 
and triplatin NC (54) can bind to 
glycans. 
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has been extensively explored. For that reason, we had to 
handpick the most noteworthy examples of platinum(II, 
IV) metallodrugs published in the literature from late 2016 
to late 2017 to be discussed in this minireview. Figure 2 
shows the structures of the selected compounds.
Expanding on the understanding of cisplatin-like 
drugs
Bruno, Lippard, Hamman and co-authors demonstra-
ted that oxaliplatin (35) kills cells by inducing ribosome 
biogenesis stress, unlike cisplatin (34) and carboplatin 
(36) that have the same effect through a DNA-damage 
response.[18] This difference in drug mechanism explains 
for example an observed lack of efficacy for oxaliplatin 
in the treatment of malignancies conventionally treated by 
cisplatin and suggests that alterations in the nature of the 
ligands in platinum complexes have deep implications for 
primary mechanisms of action. The final consequence is 
that platinum drugs might not function interchangeably 
with their derivatives in cancer chemotherapy. The authors 
suggest that the ability of oxaliplatin to cross-link DNA 
has questionable relevance in cytotoxicity, but it could still 
lead to the inhibition of rRNA synthesis, which would ulti-
mately be responsible for ribosome biogenesis stress. 
The mechanism of hypersensitivity of testicular germ 
cell tumors (TGCTs) to cisplatin was investigated by 
Awuah, Riddell, Lippard and co-authors.[24] The authors 
demonstrated that the high-mobility group box protein 
4 (HMGB4), a transcription repressor preferentially ex-
pressed in the testes that binds cisplatin-damaged DNA, 
blocks excision repair of cisplatin-DNA 1,2-intrastrand 
cross-links, increasing the sensitivity of TGCTs to cis-
platin therapy. CRISPR/Cas9-mediated gene editing was 
used to knockout the HMGB4 gene in a testicular human 
embryonic carcinoma.  Cell proliferation and apoptosis as-
says demonstrated that loss of HMGB4 elicits resistance 
to cisplatin. 
Bioconjugation
Rivilla, Cosío and co-authors described a novel 
catalytic system based on covalently modified DNA that 
promotes 1,3-dipolar reactions between azomethine ylides 
and maleimides.[19] The catalytic system makes use of the 
distortion of the double helix of DNA caused by platination 
of guanine units, similar in nature to the DNA damage 
caused by platinum chemotherapeutic drugs. As a proof of 
concept, compound 37 caused a distortion in salmon sperm 
DNA and an heterobimetallic system was generated in situ 
using Cu(OTf)2. This system was able to catalyze (3 + 2) 
cycloadditions between azomethine ylidenes and maleimides.
Muhammad, Guo, Wang and co-atuthos demonstrated 
that tethering biotin moieties to the Pt(IV) scaffold 
remarkably increases the cellular uptake of Pt in breast 
cancer cells, but lowers its accumulation in breast epithelial 
cells. [20] The mono-biotinylated Pt(IV) complex (38) was 
more active than the di-biotinylated one (39) in terms of 
reactivity and cytotoxicity.
Platinum complexes as probes of biomolecules
A very interesting luminescent probe based on 
platinum(II) complexes of 2,6-bis(benzimidazol-20 -yl)
pyridine with hexaethylene glycol methyl ether groups 
(compound 40) was developed by Zhu, Yu and co-authors[21]. 
The compound can be used for sensing lipopolysaccharide 
(LPS) endotoxin and, as consequence, it can be applied in 
a sensor for rapid discrimination between Gram-negative 
and Gram-positive bacterial pathogens. In the presence of 
LPS, 40 binds to negatively charged LPS to form LPS–
Pt(II) aggregates that enhance the intermolecular Pt/Pt 
and π- π stacking interactions, leading to a luminescence 
emission centered at 650 nm. The limit of detection of LPS 
was of 5.7 nM. As a proof-of-concept, the authors also 
demonstrated the application of 40 for rapid and washing-
free discrimination of Gram-negative E. coli and Gram-
positive S. aureus within 5 min.
Anti-HIV activity
Tsotsoros, Farrell and co-authors presented to the 
scientific community a systematic strategy to understand 
the interaction between platinum–nucleobase compounds 
and the tryptophan-containing HIV NCp7.[22] The inherent 
π–π stacking properties of the compound [Pt(chelate)
(N-donor)]2+ were modulated by systematic variation of the 
tridentate ligand (diethylenetriamine and Me-substituted 
derivatives) and N-donor (nucleobase or nucleoside), leading 
to compounds 41-52. The activity of [Pt(dien)(9-EtGua)]2+ 
(41) against HIV-1 strains BaL, NL4-3 and 91-US001 
in peripheral mononuclear blood (PBMC) cells showed 
only modest HIV inhibitory activity for the latter with an 
IC50 = 28.61 mM. Cellular accumulation studies showed no 
significant correlation with lipophilicity of the compounds, 
but all compounds had very low cytotoxicity suggesting the 
potential for antiviral applications.
Novel targets
Peterson, Farrell and co-authors demonstrated that 
heparan sulfate acts as a ligand receptor for polynuclear 
platinum anti-cancer agents.[23] Masking of extracellular 
heparan sulfate (HS) through metalloshielding resulted 
in very effective inhibition of physiologically critical 
HS functions including catalytic heparanase (HPSE) 
and protein growth factor recognition. The interaction 
of cationic polynuclear platinum complexes with the 
model HS-like pentasaccharide Fondaparinux resulted 
in inhibition of its cleavage by the HS-related enzyme 
heparanase. The end-point of inhibition of HPSE activity 
and growth factor signaling is the prevention of cell 
invasion and angiogenesis, demonstrated in HCT-116 
cells at sub-cytotoxic concentrations. A competition 
assay demonstrated that Fondaparinux can sequester the 
8+ TriplatinNC from DNA, emphasizing the strength of 
PPC–HS interactions. Altering the profile of platinum 
agents from cytotoxic to anti-metastatic has consequences 
for future directions in the development of platinum-based 
chemotherapeutics.
4. Summary and Outlook
Some important contributions were made to the field 
of gold- and platinum-based metallodrugs throughout 
the year of 2017. New classes of gold compounds were 
explored in the field of bioinorganic chemistry, such as 
gold(I)-alkyne organometallic complexes.[9] A new MS-
based technique, Ion Mobility Mass Spectrometry, was 
also employed to better characterize gold adducts to the 
nucleocapsid protein of the HIV-1 virus.[4] In the field of 
platinum chemistry, new insights were published on the 
mechanism of action of oxaliplatin, which surprisingly 
differs significantly from cisplatin and carboplatin.[18] 
Other exciting applications include bioconjugation for both 
medicinal[20] and catalytic purposes[19]. Finally, glycans 
were identified as a new class of biomolecular targets for 
polynuclear platinum complexes.[23]
References
1. S. Yei Ho, E. R. T. Tiekink, in Met. Drugs Met. Diagnostic Agents, 
John Wiley & Sons, Ltd, Chichester, UK, 2005, pp. 507–527.
2. P. J. Sadler, R. E. Sue, Met. Based. Drugs 1994, 1, 107–144.
3. R. E. F. de Paiva, Z. Du, E. J. Peterson, P. P. Corbi, N. P. Farrell, 
Inorg. Chem. 2017, acs.inorgchem.7b01762.
4. S. R. Spell, J. B. Mangrum, E. J. Peterson, D. Fabris, R. Ptak, N. 
P. Farrell, Chem. Commun. 2017, 53, 91–94.
5. Z. Du, R. E. F. de Paiva, K. Nelson, N. P. Farrell, Angew. Chemie 
Int. Ed. 2017, 56, 4464–4467.
6. S. M. Meier, C. Gerner, B. K. Keppler, M. A. Cinellu, A. Casini, 
Inorg. Chem. 2016, 55, 4248–4259.
7. A. de Almeida, A. F. Mósca, D. Wragg, M. Wenzel, P. Kavana-
gh, G. Barone, S. Leoni, G. Soveral, A. Casini, Chem. Commun. 
2017, 53, 3830–3833.
8. W. Wang, C. Zhao, D. Zhu, G. Gong, W. Du, J. Inorg. Biochem. 
2017, 171, 1–9.
9. L. Massai, L. Messori, N. Micale, T. Schirmeister, L. Maes, D. 
Fregona, M. A. Cinellu, C. Gabbiani, BioMetals 2017, 30, 313–
320.
10. E. García-Moreno, A. Tomás, E. Atrián-Blasco, S. Gascón, E. Ro-
manos, M. J. Rodriguez-Yoldi, E. Cerrada, M. Laguna, Dalton 
Trans. 2016, 45, 2462–2475.
11. J. K. Muenzner, B. Biersack, A. Albrecht, T. Rehm, U. Lacher, W. 
Milius, A. Casini, J.-J. Zhang, I. Ott, V. Brabec, et al., Chem. - A 
Eur. J. 2016, 22, 18953–18962.
12. A. Pintus, M. C. Aragoni, M. A. Cinellu, L. Maiore, F. Isaia, V. Li-
ppolis, G. Orrù, E. Tuveri, A. Zucca, M. Arca, J. Inorg. Biochem. 
2017, 170, 188–194.
13. E. V. Capparelli, R. Bricker-Ford, M. J. Rogers, J. H. McKerrow, 
S. L. Reed, Antimicrob. Agents Chemother. 2017, 61, e01947-16.
14. B. Rosenberg, L. Van Camp, T. Krigas, Nature 1965, 205, 698–
699.
15. B. Rosenberg, Platinum Complexes for the Treatment of Cancer: 
Why the Search Goes On, Verlag Helvetica Chimica Acta, 2006.
16. S. J. Berners-Price, T. G. Appleton, in Platinum-Based Drugs 
Cancer Ther. Cancer Drug Discov. Dev. (Eds.: L.R. Kelland, N.P. 
Farrell), Humana Press, Totowa, NJ, 2000, pp. 3–35.
17. E. Jerremalm, P. Videhult, G. Alvelius, W. J. Griffiths, T. Berg-
man, S. Eksborg, H. Ehrsson, J. Pharm. Sci. 2002, 91, 2116–2121.
18. A. J. Di Pasqua, D. J. Kerwood, Y. Shi, J. Goodisman, J. C. Da-
browiak, Dalton Trans. 2011, 40, 4821.
19. P. M. Bruno, Y. Liu, G. Y. Park, J. Murai, C. E. Koch, T. J. Eisen, J. 
R. Pritchard, Y. Pommier, S. J. Lippard, M. T. Hemann, Nat. Med. 
2017, 23, 461–471.
20. N. Muhammad, N. Sadia, C. Zhu, C. Luo, Z. Guo, X. Wang, 
Chem. Commun. 2017, 53, 9971–9974.
21. Y. Zhu, C. Xu, Y. Wang, Y. Chen, X. Ding, B. Yu, RSC Adv. 2017, 
7, 32632–32636.
22. S. D. Tsotsoros, P. B. Lutz, A. G. Daniel, E. J. Peterson, R. E. F. 
de Paiva, E. Rivera, Y. Qu, C. A. Bayse, N. P. Farrell, Chem. Sci. 
2017, 8, 1269–1281.
23. E. J. Peterson, A. G. Daniel, S. J. Katner, L. Bohlmann, C.-W. 
Chang, A. Bezos, C. R. Parish, M. von Itzstein, S. J. Berners-Pri-
ce, N. P. Farrell, Chem. Sci. 2017, 8, 241–252.
24, S. G. Awuah, I. A. Riddell, S. J. Lippard, Proc. Natl. Acad. Sci. U. 
S. A. 2017, 114, 950–955.
25. I. Rivilla, A. de Cózar, T. Schäfer, F. J. Hernandez, A. M. Bittner, 
A. Eleta-Lopez, A. Aboudzadeh, J. I. Santos, J. I. Miranda, F. P. 
Cossío, Chem. Sci. 2017, 8, 7038–7046.
